$LNTH
Lantheus Holdings, Inc. Stock $lnth

$lnth Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000119312516755496 Filed on November 01, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$74.35M	$73.06M	$74.12M
YoY Change	4.42%	-1.43%	-2.06%
Cost Of Revenue	$39.70M	$39.38M	$40.42M
YoY Change	4.97%	-2.56%	-8.23%
Gross Profit	$34.65M	$33.68M	$33.71M
YoY Change	3.79%	-0.07%	6.53%
Gross Profit Margin	46.6%	46.1%	45.47%
Selling, General & Admin	$18.68M	$18.80M	$17.84M
YoY Change	4.18%	5.37%	-7.89%
% of Gross Profit	53.92%	55.81%	52.93%
Research & Development	$3.710M	$2.849M	$2.458M
YoY Change	20.85%	15.91%	-19.38%
% of Gross Profit	10.71%	8.46%	7.29%
Depreciation & Amortization	$5.060M	$3.840M	$1.900M
YoY Change	68.67%	102.11%	-13.64%
% of Gross Profit	14.6%	11.4%	5.64%
Operating Expenses	$22.39M	$21.65M	$20.30M
YoY Change	6.67%	6.65%	-9.46%
Operating Profit	$12.26M	$12.60M	$13.41M
YoY Change	-1.08%	-6.06%	45.41%
Interest Expense	-$6.360M	$6.792M	$7.100M
YoY Change	-19.08%	-4.34%	-167.62%
% of Operating Profit	-51.89%	53.93%	52.95%
Other Income/Expense, Net	$440.0K	-$148.0K	-$183.0K
YoY Change	0.0%	-19.13%	-141.5%
Pretax Income	$5.740M	$4.240M	$6.125M
YoY Change	15.49%	-30.78%	-763.6%
Income Tax	$880.0K	$20.00K	$739.0K
% Of Pretax Income	15.33%	0.47%	12.07%
Net Earnings	$4.869M	$4.220M	$5.386M
YoY Change	24.34%	-21.65%	-721.22%
Net Earnings / Revenue	6.55%	5.78%	7.27%
Basic Earnings Per Share	$0.13	$0.14	$0.18
Diluted Earnings Per Share	$0.13	$0.13	$0.18
COMMON SHARES
Basic Shares Outstanding	35.72M shares	31.22M shares	30.36M shares
Diluted Shares Outstanding		32.40M shares	30.76M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$51.20M	$53.20M	$21.90M
YoY Change	79.02%	142.92%	-19.19%
Cash & Equivalents	$51.18M	$53.20M	$21.92M
Short-Term Investments
Other Short-Term Assets	$5.183M	$6.369M	$5.210M
YoY Change	34.59%	22.25%	24.05%
Inventory	$17.64M	$16.06M	$16.58M
Prepaid Expenses
Receivables	$36.82M	$34.84M	$39.72M
Other Receivables	$700.0K	$0.00	$0.00
Total Short-Term Assets	$110.8M	$110.5M	$83.44M
YoY Change	23.12%	32.4%	-6.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$94.19M	$84.98M	$92.39M
YoY Change	-1.53%	-8.02%	-3.86%
Goodwill	$15.71M	$15.71M	$15.71M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.00M	$19.73M	$20.12M
YoY Change	-2.51%	-1.95%	-27.63%
Total Long-Term Assets	$145.1M	$144.5M	$152.7M
YoY Change	-4.79%	-5.37%	-10.49%
TOTAL ASSETS
Total Short-Term Assets	$110.8M	$110.5M	$83.44M
Total Long-Term Assets	$145.1M	$144.5M	$152.7M
Total Assets	$255.9M	$255.0M	$236.1M
YoY Change	5.58%	7.98%	-9.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.94M	$13.62M	$10.70M
YoY Change	62.48%	27.26%	-30.52%
Accrued Expenses	$21.20M	$21.90M	$20.00M
YoY Change	14.59%	9.5%	-43.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$3.650M	$3.650M	$3.650M
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$43.84M	$39.12M	$34.32M
YoY Change	23.41%	13.98%	-42.42%
LONG-TERM LIABILITIES
Long-Term Debt	$274.5M	$294.6M	$350.4M
YoY Change	-21.55%	-15.92%	-12.23%
Other Long-Term Liabilities	$34.75M	$33.72M	$33.52M
YoY Change	1.77%	0.59%	-16.21%
Total Long-Term Liabilities	$309.2M	$328.3M	$383.9M
YoY Change	-19.48%	-14.48%	-12.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.84M	$39.12M	$34.32M
Total Long-Term Liabilities	$309.2M	$328.3M	$383.9M
Total Liabilities	$362.4M	$376.1M	$426.3M
YoY Change	-15.26%	-11.77%	-14.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$332.4M	-$337.3M	-$363.1M
YoY Change	-7.45%	-7.11%
Common Stock	$226.8M	$217.2M	$175.4M
YoY Change	28.99%	23.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares			0.000 shares
Shareholders Equity	-$106.5M	-$121.2M	-$190.1M
YoY Change
Total Liabilities & Shareholders Equity	$255.9M	$255.0M	$236.1M
YoY Change	5.58%	7.98%	-9.18%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	$4.869M	$4.220M	$5.386M
YoY Change	24.34%	-21.65%	-721.22%
Depreciation, Depletion And Amortization	$5.060M	$3.840M	$1.900M
YoY Change	68.67%	102.11%	-13.64%
Cash From Operating Activities	$12.78M	$15.44M	$5.420M
YoY Change	1.27%	184.87%	-73.59%
INVESTING ACTIVITIES
Capital Expenditures	-$2.420M	-$2.590M	-$2.310M
YoY Change	-48.84%	12.12%	26.92%
Acquisitions
YoY Change
Other Investing Activities	$60.00K	$1.550M	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$2.360M	-$1.050M	-$2.310M
YoY Change	-50.11%	-54.55%	44.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-12.26M	-16.09M	-3.020M
YoY Change	1078.85%	432.78%	-58.8%
NET CHANGE
Cash From Operating Activities	12.78M	15.44M	5.420M
Cash From Investing Activities	-2.360M	-1.050M	-2.310M
Cash From Financing Activities	-12.26M	-16.09M	-3.020M
Net Change In Cash	-1.840M	-1.700M	90.00K
YoY Change	-126.86%	-1988.89%	-99.22%
FREE CASH FLOW
Cash From Operating Activities	$12.78M	$15.44M	$5.420M
Capital Expenditures	-$2.420M	-$2.590M	-$2.310M
Free Cash Flow	$15.20M	$18.03M	$7.730M
YoY Change	-12.39%	133.25%	-65.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2647000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	155338000
CY2016Q3	us-gaap	Asset Retirement Obligation AssetRetirementObligation	9165000
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	72174000
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35714792	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35714792	shares
CY2016Q3	us-gaap	Assets Assets	254969000
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35724793	shares
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21922000
CY2016Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	600000
CY2016Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12216000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3341000
CY2016Q3	us-gaap	Assets Current AssetsCurrent	110465000
CY2016Q3	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	7676000
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	216814000
CY2016Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	907000
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53195000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1804000
CY2016Q3	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	8710000
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34844000
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	357000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1277000
CY2016Q3	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	455000
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	13617000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	5768000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1569000
CY2016Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1636000
CY2016Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	21850000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	138932000
CY2016Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	3650000
CY2016Q3	us-gaap	Other Assets Current OtherAssetsCurrent	6369000
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1060000
CY2016Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6951000
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	294582000
CY2016Q3	us-gaap	Inventory Net InventoryNet	16057000
CY2016Q3	us-gaap	Liabilities Liabilities	376125000
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	254969000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16406000
CY2016Q3	us-gaap	Goodwill Goodwill	15714000
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33716000
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	39117000
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1141000
CY2016Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4509000
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19728000
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4597000
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84980000
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	151473000
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	-121156000
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-337267000
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	lnth	Number Of Commercial Products NumberOfCommercialProducts	9	Item
CY2016Q3	lnth	Property Plant And Equipment In Service PropertyPlantAndEquipmentInService	79299000
CY2016Q3	lnth	Accrued Freight Costs Current AccruedFreightCostsCurrent	3435000
CY2016Q3	lnth	Inventory Raw Materials Noncurrent InventoryRawMaterialsNoncurrent	1200000
CY2016Q3	lnth	Accrued Rebates Discounts And Chargebacks Current AccruedRebatesDiscountsAndChargebacksCurrent	2593000
CY2016Q3	lnth	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	229000
CY2016Q3	lnth	Asset Retirement Obligation Liabilities Expected Present Value AssetRetirementObligationLiabilitiesExpectedPresentValue	26100000
CY2016Q3	lnth	Consolidated Fixed Charge Coverage Ratio ConsolidatedFixedChargeCoverageRatio	1	pure
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19739000
CY2015Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	490000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10525000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	157057000
CY2015Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	8145000
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	67260000
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30364501	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30364501	shares
CY2015Q4	us-gaap	Assets Assets	242379000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	90006000
CY2015Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	9137000
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	175553000
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	881000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28596000
CY2015Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	8145000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37293000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	303000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11657000
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1493000
CY2015Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	18502000
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1985000
CY2015Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	4644000
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7506000
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	349858000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	136561000
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3650000
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3851000
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Inventory Net InventoryNet	15622000
CY2015Q4	us-gaap	Liabilities Liabilities	427668000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	242379000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20496000
CY2015Q4	us-gaap	Goodwill Goodwill	15714000
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	34141000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35524000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	587000
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5709000
CY2015Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1715000
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20509000
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2407000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	86517000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	144678000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-185289000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359160000
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	lnth	Property Plant And Equipment In Service PropertyPlantAndEquipmentInService	77418000
CY2015Q4	lnth	Accrued Freight Costs Current AccruedFreightCostsCurrent	2962000
CY2015Q4	lnth	Inventory Raw Materials Noncurrent InventoryRawMaterialsNoncurrent	1200000
CY2015Q4	lnth	Accrued Rebates Discounts And Chargebacks Current AccruedRebatesDiscountsAndChargebacksCurrent	2085000
CY2015Q4	lnth	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	360000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2183000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33773000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-575000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	16648000
	us-gaap	Depreciation Depreciation	9600000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19479000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4500000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	120119000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-989000
	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	9752000
	us-gaap	Revenues Revenues	222260000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	234000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3997000
	us-gaap	Gross Profit GrossProfit	102141000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1075000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-817000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16751000
	us-gaap	Interest Expense InterestExpense	31599000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8419000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	6297000
	us-gaap	Inventory Write Down InventoryWriteDown	1073000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-790000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-15528000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2765000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18662000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2441000
	us-gaap	Operating Income Loss OperatingIncomeLoss	30142000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2041000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	8419000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-817000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	97000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1911000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	9136000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2513000
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-31599000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	73539000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22443257	shares
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	400000000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22443257	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11292000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	360438000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	26934000
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	8000000
	us-gaap	Share Based Compensation ShareBasedCompensation	1524000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	969000
	lnth	Payment For Initial Public Offering Cost PaymentForInitialPublicOfferingCost	6821000
	lnth	Tax Indemnification Income Loss TaxIndemnificationIncomeLoss	1216000
	lnth	Other Nonoperating Income Expense Others OtherNonoperatingIncomeExpenseOthers	7000
	lnth	Operating Expenses Before Gain Loss On Sale Of Assets OperatingExpensesBeforeGainLossOnSaleOfAssets	71999000
	dei	Entity Registrant Name EntityRegistrantName	LANTHEUS HOLDINGS, INC.
	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	322000
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001521036
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	698000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1869000
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	24599000
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28842000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.71
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	552000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	57000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13200000
	us-gaap	Depreciation Depreciation	6200000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.71
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	22818000
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3900000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	124370000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-330000
	us-gaap	Revenues Revenues	227503000
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	74000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	925000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	22550000
	us-gaap	Interest Expense InterestExpense	20782000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	5639000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	11000
	us-gaap	Inventory Write Down InventoryWriteDown	982000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	300000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2497000
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	6505000
	us-gaap	Gross Profit GrossProfit	103133000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1032000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1071000
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	10541000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2684000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	21893000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1658000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	490000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	552000
	us-gaap	Operating Income Loss OperatingIncomeLoss	44447000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-17958000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	4976000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	657000
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <b>1. Business Overview</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <i>Description of Business</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Holdings, a Delaware corporation, is the parent company of LMI, also a Delaware corporation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company develops, manufactures and commercializes innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers, and technologists working in a variety of clinical settings. The Company sells its products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks and group purchasing organizations. The Company sells its products globally and has operations in the United States, Puerto Rico and Canada and third-party distribution relationships in Europe, Australia, Asia Pacific and Latin America.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company’s portfolio of nine commercial products is diversified across a range of imaging procedures. The Company’s imaging agents and products include the following:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the United States, is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">TechneLite is a self-contained system, or generator, of technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Xenon Xe 133 Gas (“Xenon”) is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Neurolite is an injectable, technetium-labeled imaging agent used with Single Photon Emission Computed Tomography (“SPECT”), technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Cardiolite is an injectable, technetium-labeled imaging agent, also known by its generic name Sestamibi, used with SPECT technology in myocardial perfusion imaging (“MPI”), procedures that assess blood flow distribution to the heart.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> In the United States, the Company sells DEFINITY through its sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company’s radiopharmaceutical products are primarily distributed through third party commercial radiopharmacies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company’s International operations consist of sales directly to end users through its wholly owned radiopharmacy in Puerto Rico and sales through the Company’s distributors in Canada, Europe, Australia, Asia Pacific and Latin America.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <i>Basis of Presentation</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 2, 2016 and updated, as necessary, in this quarterly report. There were no other changes to the Company’s accounting policies since December 31, 2015.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> In the opinion of management, the accompanying unaudited condensed consolidated financial statements of Lantheus Holdings, Inc. include all normal and recurring adjustments necessary for a fair statement of the Company’s condensed consolidated financial position as of September 30, 2016 and December 31, 2015, results of operations and comprehensive earnings for the three and nine months ended September 30, 2016 and 2015, and cash flows for the nine months ended September 30, 2016 and 2015. The results of operations for the nine months ended September 30, 2016 are not necessarily indicative of the operating results to be expected for the full fiscal year or any future period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <i>Principles of Consolidation</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <i>Manufacturing and Customer Concentrations, Liquidity and Management’s Plans</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company currently relies on Jubilant HollisterStier (“JHS”) as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company recently completed its technology transfer activities at JHS and received Food and Drug Administration (“FDA”) approval for its Cardiolite product supply. The Company has technology transfer activities ongoing at Pharmalucence for the manufacture and supply of DEFINITY, but such activities have been further delayed and the Company cannot predict when or if Pharmalucence will be able to manufacture and supply DEFINITY.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Until the Company successfully becomes dual sourced for its principal products, the Company is vulnerable to future supply shortages. Disruption in the financial performance of the Company could also occur if it experiences significant adverse changes in customer mix, broad economic downturns, adverse industry or Company conditions or catastrophic external events. If the Company experiences one or more of these events in the future, it may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company has historically been dependent on key customers and group purchasing organizations for the majority of the sales of its medical imaging products. The Company’s ability to maintain and profitably renew those contracts and relationships with those key customers and group purchasing organizations is an important aspect of the Company’s strategy.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Borrowing capacity under the Company’s $50.0 million revolving credit facility (the “Revolving Facility”), is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves (the “Borrowing Base”). If the Company is not successful in achieving its forecasted operating results, the Company’s accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company’s borrowing capacity. As of September 30, 2016, the aggregate Borrowing Base was approximately $40.4 million, which was reduced by the $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $31.5 million. The Company’s senior secured term loan facility (the “Term Facility”), contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the Revolving Facility may affect the Company’s ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, the Company may be limited in utilizing its net Borrowing Base availability as a source of liquidity.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Based on the Company’s current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Revolving Facility will be sufficient to continue to fund the Company’s liquidity requirements for at least the next twelve months.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <i>Recent Accounting Pronouncements</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-15, <i>Statement of Cash Flows (Topic 230) – Classification of Certain cash Receipts and Cash Payments</i>. ASU 2016-15 will make eight targeted changes to how certain cash receipts and cash payments are presented and classified in the statement of cash flows in order to reduce existing diversity in practice. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. Adoption is required on a retrospective basis unless it is impracticable to apply, in which case the amendments for those issues are to be applied prospectively as of the earliest date practicable. The Company is currently evaluating the impact this ASU will have on our cash flows and disclosures.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> In March 2016, the FASB, issued ASU 2016-09, <i>Compensation – Stock Compensation (Topic 719), Improvements to Employee Share-Based Payment Accounting</i>. ASU 2016-09 simplifies several aspects of accounting for employee share-based payment transactions, including the accounting for income tax consequences, the classification of awards as either equity or liabilities, an accounting policy election for forfeitures, statutory tax withholding requirements and certain classifications on the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> In February 2016, the FASB, issued ASU 2016-02, <i>Leases (Topic 842)</i>. ASU 2016-02 supersedes the existing guidance for lease accounting, <i>Leases (Topic 840)</i>. ASU 2016-02 was issued to increase transparency and comparability among organizations by requiring lessees to recognize all lease transactions (with terms in excess of 12 months) on the balance sheet as a lease liability and a right-of-use asset (as defined). The accounting for lessors remains largely unchanged. ASU 2016-02 retains a distinction between finance leases and operating leases. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize a lease liability and right-of-use asset. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact this ASU will have on our financial position, results of operations, cash flows and disclosures.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> In May 2014, the FASB issued ASU 2014-09, <i>Revenue from Contracts with Customers (Topic 606</i>) or ASU 2014-09. ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. In August 2015, the FASB issued ASU 2015-14, <i>Revenue from Contracts with Customers (Topic 606), Deferral of the Effective Date</i>, which defers the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017 with early adoption permitted as of its original effective date of December 15, 2016. In March 2016 and April 2016, the FASB issued ASU 2016-08, <i>Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net) </i>and ASU 2016-10, <i>Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing,</i> respectively, which further clarifies the implementation guidance on principal versus agent considerations, identification of performance obligations and accounting for intellectual property licenses. In May 2016, the FASB issued ASU 2016-12, <i>Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients </i>or ASU 2016-12, which provides clarification on assessing the collectability criterion, presentation of sales taxes, measurement date for noncash consideration and completed contracts at transition. The Company is currently evaluating the impact these ASUs will have on our financial position, results of operations, cash flows and disclosures.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	36861000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	445000
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-20782000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	41600000
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.</p> </div>
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31049351	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30657623	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	61000
	dei	Trading Symbol TradingSymbol	LNTH
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8493000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	61000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	27856000
	us-gaap	Share Based Compensation ShareBasedCompensation	1869000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	57790000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	Segment
	lnth	Payment For Initial Public Offering Cost PaymentForInitialPublicOfferingCost	1266000
	lnth	Debt Retirement Cost DebtRetirementCost	1415000
	lnth	Financial Assurance In Form Of Surety Bond FinancialAssuranceInFormOfSuretyBond	28200000
	lnth	Tax Indemnification Income Loss TaxIndemnificationIncomeLoss	632000
	lnth	Incremental Common Shares Attributable To Restricted Stock Awards IncrementalCommonSharesAttributableToRestrictedStockAwards	391728	shares
	lnth	Financial Assurance In Form Of Letter Of Credit FinancialAssuranceInFormOfLetterOfCredit	8800000
	lnth	Percentage Of Greatest Amount Of Letter Of Credit Drawn PercentageOfGreatestAmountOfLetterOfCreditDrawn	1.05	pure
	lnth	Other Nonoperating Income Expense Others OtherNonoperatingIncomeExpenseOthers	-2000
	lnth	Operating Expenses Before Gain Loss On Sale Of Assets OperatingExpensesBeforeGainLossOnSaleOfAssets	65191000
	lnth	Other Comprehensive Income Loss Reclassification Adjustment Due To Sale Of Group Of Assets Liabilities Not Qualifying As Discontinued Operations OtherComprehensiveIncomeLossReclassificationAdjustmentDueToSaleOfGroupOfAssetsLiabilitiesNotQualifyingAsDiscontinuedOperations	-435000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9206000
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.18
CY2015Q3	us-gaap	Depreciation Depreciation	1900000
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4943000
CY2015Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	40418000
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-628000
CY2015Q3	us-gaap	Revenues Revenues	74123000
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-183000
CY2015Q3	us-gaap	Gross Profit GrossProfit	33705000
CY2015Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-443000
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6125000
CY2015Q3	us-gaap	Interest Expense InterestExpense	7100000
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5386000
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	112344	shares
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	13408000
CY2015Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-443000
CY2015Q3	lnth	Tax Indemnification Income Loss TaxIndemnificationIncomeLoss	439000
	us-gaap	Share Based Compensation ShareBasedCompensation	877000
	lnth	Debt Retirement Cost DebtRetirementCost	1415000
	lnth	Tax Indemnification Income Loss TaxIndemnificationIncomeLoss	196000
	lnth	Incremental Common Shares Attributable To Restricted Stock Awards IncrementalCommonSharesAttributableToRestrictedStockAwards	1084571	shares
	lnth	Other Nonoperating Income Expense Others OtherNonoperatingIncomeExpenseOthers	-1000
	lnth	Operating Expenses Before Gain Loss On Sale Of Assets OperatingExpensesBeforeGainLossOnSaleOfAssets	21646000
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	739000
CY2015Q3	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-7100000
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30761771	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30359516	shares
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2458000
CY2015Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8633000
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	591000
CY2015Q3	lnth	Incremental Common Shares Attributable To Restricted Stock Awards IncrementalCommonSharesAttributableToRestrictedStockAwards	289911	shares
CY2015Q3	lnth	Other Nonoperating Income Expense Others OtherNonoperatingIncomeExpenseOthers	6000
CY2015Q3	lnth	Operating Expenses Before Gain Loss On Sale Of Assets OperatingExpensesBeforeGainLossOnSaleOfAssets	20297000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10091000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
	us-gaap	Depreciation Depreciation	2100000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4889000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	39382000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-349000
	us-gaap	Revenues Revenues	73063000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-154000
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	560000
	us-gaap	Gross Profit GrossProfit	33681000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	669000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4240000
	us-gaap	Interest Expense InterestExpense	6786000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4220000
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	96849	shares
	us-gaap	Operating Income Loss OperatingIncomeLoss	12595000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	234000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-6786000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32402297	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31220877	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2849000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8706000
	lnth	Other Comprehensive Income Loss Reclassification Adjustment Due To Sale Of Group Of Assets Liabilities Not Qualifying As Discontinued Operations OtherComprehensiveIncomeLossReclassificationAdjustmentDueToSaleOfGroupOfAssetsLiabilitiesNotQualifyingAsDiscontinuedOperations	-435000

Files In Submission

Name	View Source	Status
0001193125-16-755496-index-headers.html	Edgar Link	pending
0001193125-16-755496-index.html	Edgar Link	pending
0001193125-16-755496.txt	Edgar Link	pending
0001193125-16-755496-xbrl.zip	Edgar Link	pending
d245336d10q.htm	Edgar Link	pending
d245336dex101.htm	Edgar Link	pending
d245336dex102.htm	Edgar Link	pending
d245336dex311.htm	Edgar Link	pending
d245336dex312.htm	Edgar Link	pending
d245336dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lnth-20160930.xml	Edgar Link	completed
lnth-20160930.xsd	Edgar Link	pending
lnth-20160930_cal.xml	Edgar Link	unprocessable
lnth-20160930_def.xml	Edgar Link	unprocessable
lnth-20160930_lab.xml	Edgar Link	unprocessable
lnth-20160930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LNTH
Lantheus Holdings, Inc. Stock $lnth

2016 Q4 Form 10-Q Financial Statement

#000119312516755496 Filed on November 01, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNTH Lantheus Holdings, Inc. Stock $lnth

2016 Q4 Form 10-Q Financial Statement

#000119312516755496 Filed on November 01, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNTH
Lantheus Holdings, Inc. Stock $lnth